Efficacy of Intramuscular Diclofenac for Pain Relief in Women Undergoing Hysterosalpingography in Ahmadu Bello University Teaching Hospital, Zaria: A Randomized Controlled Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202103490512646

Enrollment

Registered

2021-03-02

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female

Interventions

Intramuscular Diclofenac

Placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: i. Women of reproductive age. ii. All consenting women presenting at the gynecologic clinic indicated for HSG for the evaluation of tubal factor infertility.

Exclusion criteria

Exclusion criteria: i.Acute pelvic infection ii.Genital tuberculosis ii.Allergy to contrast iv.Allergy to NSAIDs v.Unexplained vaginal discharge vi.Unexplained vaginal bleeding vii.Chronic pelvic pain vii.Recent or chronic use of NSAIDs

Design outcomes

Primary

Measure	Time frame
difference in mean pain scores during cervical instrumentation and contrast instillation	—

Secondary

Measure	Time frame
1. Difference in mean pain scores at 5 and 30 minutes post Hsg 2. Number of patient needing a additional analgesics after hsg 3. To determine side effects of Diclofenac	—

Countries

Nigeria

Contacts

Public ContactGabriel Dogbanya

Consultant

angelgabe3j@gmail.com+2348030790966

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026